

The Evolution of LifeArc, a Translational Organisation

Netval 16th September 2019

Pauline Stasiak PhD

Investment Principal, Seed Fund

feArc

ACADEMIC AND
NON PROFIT
Institutions



Technology Transfer

- **7 Business Managers: identification, protection and commercialisation of IP for the MRC and LSHTM**
- **MRC Portfolio:**
 - 563 IP assets of which 26% are patented
 - 67% of the patent portfolio is partnered; Of the remainder, 55% are being actively marketed and 25% have attracted interest from commercial partners
 - £22.3m gross income from commercialisation activities
- **MRC 2018-19:**
 - 55 new invention disclosures
 - 9 patent filings
 - 23 new licenses

Supporting Charities: Research to Patient

Portfolio Review

- Identifying, and where feasible, support research outcomes with the potential to deliver patient impact
- Ensuring funded research is protected & progressed for patient benefit

Advisory Service

- Ts & Cs review
- Update application and reporting forms to capture translational activities
- Revenue sharing guidelines
- Setting up collaborations
- Industry Engagement
- Drug discovery expertise in-house
- Therapeutic due diligence
- Marketing and IP advice

LifeArc-AUTM Technology Transfer Career Training Fellowships

Aim: *to ease entry into the TT profession by providing TT training and practical experience*

Who is it for? *Life Scientist- Europe based*

What it provides:

- *12 months technology transfer training program*
- *Attendance at local and international technology transfer conferences*
- *Mentor and career support*
- *Assistance to secure practical experience through an internship (optional)*

All 2017-18 candidates secured a permanent TT position by the end of the fellowship

2019-2019 applicants include 5 UK based fellows and 2 EU fellows

Applications for 2019-20 LifeArc-AUTM fellows closed in July

Contact Anji.Miller@lifearc.org for more information; (www.lifearc.org/careers/fellowships)

The Centre for Therapeutics Discovery

Bridging the gap between basic research and early drug discovery

Working with industry, charities and universities

A purpose built LifeArc facility opened April 2016

> 90 scientists

State-of-the-art equipment and capabilities


Biology, Chemistry and Biotherapeutics teams in one place offers unique flexibility

Focus on, and collaborations in;

- neuroscience
- antimicrobials
- oncology



LifeArc
Centre for
Therapeutics
Discovery



The Centre for Diagnostics Development

- Relocation to a purpose built facility 2017
- A team with significant industry experience in molecular diagnostics
- A regulatory compliant system
- Translate early stage diagnostic opportunities working collaboratively with academics, clinicians & industry partners to realise opportunities, build effective diagnostic tools & bring patient benefit



LifeArc Success in Numbers

70 antibodies humanised over the last 30 years

- Mouse, rat, rabbit, hamster, llama, nanobodies

20 entered in clinical trials

- To our knowledge, none failed for immunogenicity or reasons related to antibody properties

6 antibodies currently in clinical trials

4 humanised antibodies currently on the market

- Tysabri, Actemra, Entyvio and Keytruda


We are Self-Funded from Revenues



CD / UC



RA



MS



Cancer

LifeArc's Funds

LifeArc supports the development of novel therapeutics through its Funds:



- **Seed Fund**
 - £25 million to invest, over the next four years, in early stage UK therapeutics companies that focus on diseases with high unmet need
 - Any financial return will be re-invested to ensure that the fund is sustainable
- **Philanthropic Fund**
 - Awards grants, either directly to academics or together with rare disease charity partners
 - Qualifying projects must show a strong scientific rationale along with a credible development path
 - LifeArc will not ask for any financial return or intellectual property (IP) rights

Seed Fund Mission Statement

- The LifeArc Seed Fund is an early stage investor in biomedical start-ups, working with the wider LifeArc community and focussed on addressing the funding shortage between innovative science and venture investment in order to better deliver clinical benefit to the patient
- A venture facing, and therefore market and demand-driven fund, thereby fulfilling LifeArc's mission of deliverability to the patient

Strategic Context

- There is a shortage (rather than gap) in the UK funding environment for intelligent institutional capital to bridge from innovative science to venture investment and beyond to the patient
- LifeArc is financially equipped to help ameliorate this funding shortage and open up a new front to fulfil its mission of bringing innovative new medicines and diagnostics to the patient
- LifeArc is well positioned to lever its existing capabilities in this activity – deal sourcing, value-adding services, existing relationships, to provide a real USP in the seed space
- The “Philanthropic Fund:Seed Fund:Venture Fund” is a powerful axis addressing market needs for joined up financing from first investment to exit

Seed Fund Strategy – Basic Parameters

- **Scope: therapeutics (possibly also compelling diagnostics)**
- **Focus: will include but not be limited to; immune oncology, neurodegeneration, respiratory, AMR, metabolic and anti-inflammatory**
- **Business model: focussing on innovation and credible path to approval and patient use**
- **Geography: UK**
- **Portfolio size: 10 – 12. Invested over a four year period**
- **Investment size: up to £2.5m total per investee**
- **Early VC endorsement (a proxy for market “pull”)**

Typical Attributes of a Potential Investee

- Strong IP position
- Reputable scientists and institution
- Clinical validation of potential deliverables
- Demonstrable market pull – via VC, and/or industry/key adopters
- Good quality co-investors (if required)
- An existing company with a business plan
- A commercial champion engaged

Thank you!

Dr Pauline Stasiak

pauline.stasiak@lifearc.org

www.lifearc.org